

Why Andes Virus is Triggering Post-Covid Anxiety

*What this reveals about preparedness, public anxiety, and the
future of health communication.*

May 2026



OMNICOM
HEALTH

Introduction

The recent Andes hantavirus outbreak is a reminder that the next global health concern may not look like COVID-19 — but it will still be interpreted through COVID-shaped memory. Future outbreaks may be smaller, more localized and more ecologically specific than COVID, but in a hyperconnected world, even localized threats can quickly become global trust tests.

Hantaviruses are lesser known but not new. They are typically rodent-borne viruses that can cause severe disease, including hantavirus pulmonary syndrome, also called hantavirus cardiopulmonary syndrome. What makes Andes virus particularly attention-grabbing is its rare but documented ability to spread between people through close and prolonged contact.

The bigger challenge is communication. For pharma and healthcare communicators, Andes hantavirus is a reminder that preparedness is not only about products, surveillance or clinical protocols. It also requires clear risk framing, visible readiness and science-based messaging that avoids both alarmism and minimization.



Fear's Long Memory: How COVID Reshaped Health Anxiety and the New “Infection Imagination”

For consumers, the rise of viruses that appear capable of spreading between people is not just a scientific story — it is an emotional one. COVID-19 changed the public’s relationship with infectious disease. Before 2020, many people saw outbreaks as distant, seasonal or geographically contained. Today, even a small cluster can trigger immediate associations with cruise ship outbreaks, quarantine, travel disruption, border closures, delayed diagnoses, medical evacuation and uncertainty about who is actually “safe.”

This has created a form of post-COVID health vigilance. People are more informed than before, but also more primed for fear. In the case of Andes hantavirus, nuance matters: this is not a highly transmissible respiratory virus like SARS-CoV-2, and transmission appears limited and associated with close, prolonged exposure. But nuance often travels more slowly than anxiety.

Consumers now expect fast, transparent, plain-language communication. They want to know: What is the risk to me? What symptoms should I watch for? Can I travel? Should I isolate? Is there treatment? Who is responsible for telling me? In the absence of clear answers, people fill the gap with social speculation, outdated memories of COVID restrictions and mistrust of institutions. The public-health challenge is therefore not only to contain disease, but to contain uncertainty.



Rodents, Respiratory Illness, and Reality: What Healthcare Teams Need to Know: The Medical Perspective


Medically, Andes virus sits at the intersection of zoonotic disease, respiratory illness and outbreak preparedness. Hantavirus pulmonary syndrome is a serious condition that can begin with fever, muscle aches, headache or gastrointestinal symptoms and, in severe cases, progress rapidly to cough, shortness of breath, respiratory distress, pulmonary edema, shock and cardiopulmonary collapse.

Most hantaviruses are transmitted from rodents to humans through environmental exposure, particularly contact with infected rodent urine, droppings, saliva or nesting materials. Exposure can occur when contaminated particles become aerosolized during cleaning, sweeping or disturbing cabins, sheds, rural homes, agricultural spaces or forested environments. This makes Andes hantavirus fundamentally different from COVID-19, whose primary pathway was routine respiratory spread in everyday community settings.

What distinguishes Andes virus is its documented ability, in rare circumstances, to spread between humans. This is typically associated with close and prolonged contact, including household members, intimate partners, caregivers or healthcare settings without appropriate precautions. However, this is not the same as sustained, efficient community transmission like SARS-CoV-2 or influenza.

The clinical implications are significant. Because early symptoms are non-specific, travel history, environmental exposure and contact history become critical diagnostic tools. In an outbreak setting, clinicians need rapid access to testing, clear case definitions, PPE guidance, escalation pathways and cross-border reporting.

The more accurate framing is that Andes hantavirus is a regionally endemic, high-consequence zoonotic virus with limited person-to-person potential. That distinction matters: it allows healthcare teams to act with urgency without amplifying unnecessary panic.



Brand Behavior Under Glass: When Healthcare Companies Earn Credibility in Crisis: From Crisis Response to Preparedness Infrastructure

COVID-19 was a turning point for healthcare marketing and industry engagement. For the first time at global scale, vaccine manufacturers, diagnostic companies, public-health agencies and treatment developers became household names. Scientific platforms — mRNA, antivirals, rapid testing and variant surveillance — entered mainstream conversation.

Pharma brands were no longer communicating only with clinicians, payers and regulators. They were speaking, directly or indirectly, to everyone. Emerging infectious threats such as Andes hantavirus raise a critical question for the pharmaceutical industry: **how do we move from crisis response to crisis preparedness?**

The post-COVID mandate for pharma cannot be limited to developing products after a crisis is already visible. The industry should be building capabilities for rare, severe and zoonotic pathogens before the commercial case is obvious. That means investing in flexible vaccine, monoclonal antibody, antiviral and diagnostic platforms that can be adapted rapidly to emerging threats.

For marketers and pharma brands, the implication is clear: outbreak readiness is now a reputational capability. Companies need to know what role they are prepared to play before they are pulled into the public conversation. That role may not always be product promotion. In many cases, it may be education, myth correction, HCP support, patient navigation, diagnostic awareness, clinical trial information or partnership with public-health bodies.





This requires a different model of brand behavior. In a health crisis, the most credible brands do not simply increase visibility; they increase usefulness. They provide clear, medically accurate, actionable information. They acknowledge uncertainty. They explain what is known, what is not yet known and what people should do next. They avoid opportunism, fear-based messaging or premature commercial claims.

People are scanning for signals: Are officials moving quickly? Are companies paying attention? Are we being told the truth? Is this being minimized? Is it being exaggerated? The post-COVID consumer does not need vague reassurance. They need specificity, humility and visible preparedness. For Andes hantavirus specifically, that means communicating clearly: this is not new; it is not COVID; rodent exposure remains the primary risk; person-to-person transmission is possible but limited; and people with relevant exposure or symptoms should be taken seriously.

For healthcare marketers, several actions should now be considered part of preparedness infrastructure:

- Scenario planning before the crisis hits: Brands should map how different outbreak scenarios could affect patients, HCPs, supply chains, field teams, media scrutiny and public trust.
- Rapid medical/legal/regulatory review models: Crisis moments move faster than traditional approval timelines. Companies need pre-agreed processes for urgent, compliant communication.
- Plain-language content libraries: Patient-facing explainers, symptom guides, exposure checklists, FAQ documents and myth-versus-fact materials should be prepared in advance and adapted quickly.
- HCP education and escalation tools: Clinicians need concise resources on exposure history, early symptoms, testing pathways, reporting requirements and when to involve public-health authorities.
- Social listening and misinformation response: Brands should monitor emerging fears, false claims and knowledge gaps, then respond with evidence-based content that is calm, human and shareable.
- Stakeholder coordination: Communications should be aligned with public-health agencies, medical societies, academic experts, advocacy groups, local health systems and travel-health networks.
- Equity-by-design planning: Outbreak preparedness must consider rural, occupationally exposed, geographically remote and endemic communities from the start, not as an afterthought.





Whether a company markets a vaccine, a diagnostic, a therapy, a disinfectant, a travel-health service or a hospital solution, consumers increasingly judge health brands by how they behave when the system is under stress. Global health crises require go-to-market models that are more adaptive, more medically integrated and more reputation-aware.

Brands that bring clarity and credibility to moments of uncertainty can build trust; those that appear slow, confused or self-serving can quickly erode it.

Disease Crosses Borders Faster Than Decision-Making

The Andes hantavirus cruise cluster also illustrates the public-policy complexity of modern outbreaks. Ships, aircraft and global tourism create mobile exposure networks. A person may be infected in one country, become symptomatic in another, receive care in a third and have close contacts across many more.

This creates difficult policy questions. Which country accepts patients for evacuation? Who pays? How do authorities balance humanitarian care with domestic political pressure? How do they prevent stigmatizing passengers or nationalities? How should countries coordinate when scientific certainty is incomplete?

The willingness — or reluctance — of countries to receive exposed or symptomatic travelers can become a visible measure of global solidarity. During COVID-19, border closures, flight bans and quarantine policies showed how quickly health risk becomes geopolitical. The same dynamics can reappear in smaller outbreaks: countries may fear importing disease, health systems may resist capacity strain, and leaders may prioritize domestic optics.

But pathogens exploit fragmentation. If countries hesitate to share data, accept patients, coordinate testing or align monitoring protocols, the result is slower containment and lower public trust.

Public policy must therefore evolve from national protection toward networked preparedness. That means interoperable surveillance, transparent risk assessment, pre-agreed medical evacuation protocols, data-sharing mechanisms and clear guidance for travel operators.

It also means communicating proportionality: strong precautions without exaggerated alarm; border awareness without border panic.

Conclusion:

The next outbreak may be biologically different from COVID — but socially, it will arrive in COVID's shadow

Andes hantavirus is not COVID-19. But the situation matters because it reveals a changed world: consumers are anxious, clinicians need speed and specificity, healthcare companies are expected to communicate responsibly, and governments must coordinate across borders in real time.

The central lesson is that infectious-disease preparedness is no longer only a public-health discipline. It is also a trust discipline. The organizations that will lead most effectively — whether governments, healthcare companies, agencies or medical institutions — will be those that can translate uncertainty into clarity, science into action and caution into confidence.

In a post-COVID world, that means building the capabilities, partnerships, communication strategies and equity commitments now — before the next outbreak signal arrives.

Keep the conversation going:

If you're interested in learning more or keeping the conversation going, we'd love to connect. Reach out to our team at omnicomhealthmarketing@omnicomhealthgroup.com